ASCC3 and prostate carcinoma: To investigate whether ASCC3 influences removal of aberrant methylbases from the mRNA pool, WT and ASCC3-deficient PC-3 prostate cancer cells (Fig. 5A) were subjected to MMS treatment for 1 h and the levels of m1A, m3C and m7G in mRNA were quantified in at various time points.